培美曲塞联合吉非替尼对晚期肺腺癌患者的疗效

Curative Effect of Pemetrexed Combined with Gefitinib on Patients with Advanced Lung Adenocarcinoma

目的:探讨培美曲塞联合吉非替尼对晚期肺腺癌患者的疗效。方法:选取2018年1月至2020年12月在郑州大学第一附属医院治疗的92例晚期肺腺癌患者,随机分为对照组与观察组,各46例。对照组单用吉非替尼治疗,观察组使用培美曲塞联合吉非替尼治疗,比较两组患者的近期疗效、不良反应、肿瘤标志物水平、生存情况、生活质量。结果:观察组客观缓解率为65.22%、疾病控制率为86.96%,明显高于对照组的45.65%、73.91%,差异具有统计学意义(P<0.05);观察组治疗后癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平均低于对照组,差异具有统计学意义(P<0.05);观察组无进展生存时间、总生存时间均长于对照组,差异具有统计学意义(P<0.05);观察组治疗后躯体状况、情感状况、功能状况、社会/家庭状况、肺癌特异模块、肺癌治疗功能评价量表(FACT-L)总分均高于对照组,差异具有统计学意义(P<0.05)。结论:培美曲塞联合吉非替尼对晚期肺腺癌的疗效较好,能增强对肿瘤的抑制力,降低肿瘤标志物水平,延长生存时间,提高生存质量,且不增加不良反应发生率。

Objective To investigate the therapeutic effect of pemetrexed combined with gefitinib on patients with advanced lung adenocarcinoma.Methods A total of 92 patients with advanced lung adenocarcinoma treated in the First Affiliated Hospital of Zhengzhou University from January 2018 to December 2020 were randomly divided into a control group and an observation group,with 46 cases in each group.The control group was treated with gefitinib monotherapy,and the observation group was treated with pemetrexed combined with gefitinib.The short-term efficacy,adverse reactions,tumor marker levels,survival and quality of life of patients in the two groups were compared.Results The objective remission rate and disease control rate in the observation group were 65.22% and 86.96%,respectively,which were significantly higher than 45.65% and 73.91% in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The progression-free survival time and overall survival time in the observation group were longer than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of physical status,emotional status,functional status,social/family status,functional assessment of cancer therapy(FACT-L)scale in the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion Pemetrexed combined with gefitinib has a good therapeutic effect in patients with advanced lung adenocarcinoma,which can enhance tumor inhibition,reduce the level of tumor markers,prolong the survival time,improve the quality of life,and do not increase the incidence of adverse reactions.